Long-term course of ambulatory patients with COVID-19 initially treated with enoxaparin vs no anticoagulation: final analysis of the OVID (enoxaparin for outpatients with COVID-19) randomized trial

Background: Early thromboprophylaxis does not prevent hospital admissions and death among outpatients with symptomatic COVID-19. Its impact on long-term outcomes, including long COVID symptoms and performance status, is unknown. Objectives: To assess the long-term effects of thromboprophylaxis given...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Riccardo M. Fumagalli, Davide Voci, Behnood Bikdeli, Roland Bingisser, Giuseppe Colucci, Gabor Forgo, Teresa Gerardi, Bernhard Gerber, Alexandru Grigorean, Frederikus A. Klok, Marc Righini, Helia Robert-Ebadi, Stefan Stortecky, Silvia Ulrich, Simon Wolf, Dörte Wyss, Lukas Hobohm, Nils Kucher, Stefano Barco, Ulrike Held, Tim Sebastian, Daniel Duerschmied, André Frenk, Andrea Götschi, Stavros V. Konstantinides, François Mach, Thomas Rosemann, Noemi R. Simon, Hervé Spechbach, David Spirk, Lukas Vaisnora, Stéphanie Roth Zetzsche, Rebecca Spescha, Claudia Leeger, Yulia Butscheid, Eliane Probst, Evy Micieli, Fabian Johner, Georgios Vatsakis, Dagmar Keller Lang, Silvana Rampini Speck, Barbara Hasse, Marco Rueegg, Isabelle Arnold, Christian Nickel, Jeannette Busch, Marc Blondon, Frédéric Glauser, Micol G. Cittone, Chiara Kessler, Diona Gjermeni, Christoph B. Olivier, Nadine Gauchel, Paul Biever, Dorothea Becker, Marc Schindewolf, Arnaud Kuenzi
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2024-07-01
coleção:	Research and Practice in Thrombosis and Haemostasis
Assuntos:	COVID-19 heparin long COVID quality of life thrombosis
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2475037924002292
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!